ABT-110

ABT-110
[[File:|frameless|220px|alt=|Chemical structure of ABT-110]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

ABT-110 is an investigational drug developed by AbbVie, a global biopharmaceutical company. It is primarily studied for its potential therapeutic effects in treating certain types of cancer. ABT-110 is classified as a small molecule inhibitor, targeting specific pathways involved in cancer cell proliferation and survival.

Mechanism of Action

ABT-110 functions by inhibiting specific proteins that are crucial for the growth and survival of cancer cells. It is designed to interfere with the signaling pathways that promote tumor growth, thereby inducing apoptosis, or programmed cell death, in cancerous cells. The exact molecular targets of ABT-110 are proprietary, but it is known to affect pathways commonly dysregulated in cancer.

Clinical Development

ABT-110 is currently in the early stages of clinical development. Preclinical studies have shown promising results in vitro and in animal models, demonstrating its potential efficacy in reducing tumor size and inhibiting metastasis. The drug is undergoing Phase I clinical trials to evaluate its safety, tolerability, and pharmacokinetics in humans.

Potential Indications

While the primary focus of ABT-110 is on oncology, particularly in solid tumors, research is ongoing to explore its efficacy in other indications. The drug's ability to target specific cancer pathways makes it a candidate for combination therapy with other anticancer agents.

Side Effects and Safety

As with many investigational drugs, the safety profile of ABT-110 is still being established. Common side effects observed in early trials include mild to moderate nausea, fatigue, and headache. Serious adverse effects are rare but are being closely monitored as clinical trials progress.

Research and Future Directions

Ongoing research aims to better understand the pharmacodynamics and pharmacokinetics of ABT-110, as well as its long-term effects on patients. Future studies will likely focus on optimizing dosing regimens and exploring its use in combination with other therapies to enhance its anticancer effects.

Also see

• Cancer treatment
• Small molecule inhibitors
• Clinical trials
• AbbVie

This article is a stub related to pharmacology. You can help WikiMD by expanding it!